Loading organizations...

§ Private Profile · Nashville, TN, USA
CDMO providing integrated drug development, testing, and manufacturing for pharmaceutical clients, focused on sterile injectables.
August Bioservices is a Nashville, Tennessee-based contract development and manufacturing organization that provides drug discovery, formulation, testing, and commercial manufacturing services for sterile injectables. Operating under a standard fee-for-service model, the company supports pharmaceutical and biotechnology firms by managing therapeutic development from lab-scale research through commercial production. Backed by lead investor Oak HC/FT, the enterprise secured a $65 million expansion investment in 2020 to scale its clinical capabilities while partnering with Optima for advanced fill-finish systems. This capital injection funded the construction of a new sterile manufacturing facility designed to increase liquid and lyophilized filling capacity, a project projected to add approximately 350 jobs to the local economy. Led by Chief Executive Officer Jenn Adams, the organization was originally formed during 2018 as PMI BioPharma Solutions before officially rebranding to its current name in 2020.
August Bioservices has raised $89.0M across 2 funding rounds.
August Bioservices has raised $89.0M in total across 2 funding rounds.
August Bioservices has raised $89.0M across 2 funding rounds. Most recently, it raised $65.0M Series B in November 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2022 | $65M Series B | OAK HC/FT, Andrew Adams | F Prime Capital, Polaris Partners, Polaris Partners | Announced |
| May 1, 2021 | $24M Series A | Brian Chee | F Prime Capital, OAK HC/FT, Polaris Partners | Announced |
August Bioservices has raised $89.0M in total across 2 funding rounds.
August Bioservices's investors include Oak HC/FT, Andrew Adams, F-Prime Capital Partners, Polaris Partners, Brian Chee.
August Bioservices is not a technology company in the traditional sense—it is a Contract Development and Manufacturing Organization (CDMO) specializing in sterile injectable pharmaceuticals[1][4]. While it employs advanced technology and cutting-edge science, its primary business is providing drug development, testing, and manufacturing services to biotech and pharmaceutical clients, not building or selling technology products.
August Bioservices is a US-based CDMO headquartered in Nashville, Tennessee, that provides end-to-end pharmaceutical development and manufacturing services for sterile injectable medications[4]. The company serves biotech and pharmaceutical companies of all sizes, from preclinical through commercial stages, offering a comprehensive one-stop-shop approach[2].
The organization focuses on solving a critical industry problem: bringing sterile injectable products from development to commercialization efficiently and safely. Its clients range from early-stage biotech firms to established pharmaceutical companies seeking specialized expertise in complex formulations, poorly soluble compounds, and uncommon container sizes[2][3]. August Bioservices' value proposition centers on quality, scalability, and speed—enabling clients to accelerate the advancement of novel therapeutics while minimizing regulatory risk[1].
August Bioservices was established in July 2020 and headquartered in Nashville, Tennessee[6]. The company emerged during a period of significant growth in the CDMO sector, driven by increasing demand from biotech companies for specialized manufacturing partners. Since its founding, the organization has pursued aggressive expansion activities, including a major facility renovation and the construction of additional manufacturing lines to scale operations[6]. This growth trajectory reflects both the company's early success and the broader market demand for sterile injectable manufacturing capacity.
August Bioservices operates within a structural shift in the pharmaceutical industry toward outsourced manufacturing. As drug development has become more specialized and capital-intensive, companies increasingly rely on CDMOs rather than building internal manufacturing capacity. August's focus on sterile injectables positions it within a high-demand segment—injectable therapies represent a growing portion of the pharmaceutical pipeline, particularly for biologics and complex small molecules.
The company's Nashville location and expansion strategy also reflect broader trends of pharmaceutical manufacturing decentralization beyond traditional pharma hubs, bringing specialized manufacturing capacity to underserved regions while supporting local economic development[6].
August Bioservices is well-positioned to capture growth in the sterile injectable CDMO market, driven by increasing demand for specialized manufacturing partners and the company's demonstrated commitment to capacity expansion. The organization's emphasis on quality, technical expertise, and integrated services addresses genuine pain points for biotech clients navigating complex regulatory requirements and scale-up challenges.
The company's trajectory will likely depend on its ability to execute facility expansions, maintain quality standards at scale, and deepen relationships with clients moving products toward commercialization. As the pharmaceutical industry continues to outsource manufacturing and as injectable therapies gain prominence in drug pipelines, August's specialized positioning offers meaningful competitive advantages—provided it can sustain operational excellence while scaling rapidly.